Erol Erduran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Erol Erduran has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
Aysenur Bahadir
Pediatric Hematology-Oncology, Division of Pediatric Hematology-Oncology †Pediatric Surgery, Division of Pediatric Surgery §Radiation Oncology, Division of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon ‡Pediatric Hematology-Oncology, Division of Erzurum Regional Training and Research Hospital, Erzurum, Turkey
5 shared publications- Aysenur Bahadir
Karadeniz Teknik University, Faculty of Medicine, Division of Pediatric Hematology and Oncology, Department of Pediatrics, Trabzon, Türkiye
5 shared publications - Gökçe Pinar Reis
Faculty of Medicine, Department of Paediatric Haematology and Oncology, Karadeniz Teknik University, Trabzon, Turkey
3 shared publications - Zeynep Gökçe Gayretli Aydın
Department of Pediatric Infectious Diseases, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
3 shared publications - Adem Karbuz
Council of Forensic Medicine, Ministry of Justice, Republic of Turkiye, Istanbul, Turkiye
2 shared publications - Ahmet Soysal
Clinic of Pediatrics, Memorial Ataşehir Hospital, İstanbul, Türkiye
2 shared publications
Latest Publications
- 3 September 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (7) , e323-e328
Oral Cyanocobalamin Treatment in Infants Under 1 Year With Nutritional Vitamin B12 Deficiency: A Retrospective Comparison of 500 and 1000 µg Dose Regimens
Background: Vitamin B12 deficiency is a significant health problem in infancy, particularly in developing countries. Oral treatment has emerged as an alternative to intramuscular therapy, but optimal dosing in infants remains unclear. Methods: This retrospective study included 93 infants aged 1 to 12 months diagnosed with nutritional vitamin B12 deficiency. Patients received either 500 or 1000 µg oral cyanocobalamin. Laboratory parameters were evaluated at baseline, 2 months, and 4 months. Results: Both treatment groups demonstrated significant increases in serum vitamin B12 levels and decreases in homocysteine levels ( P <0.001). No significant difference was observed between the 500 and 1000 µg groups regarding hematological or biochemical response. Treatment was well tolerated with no reported adverse effects. Conclusions: Oral cyanocobalamin was associated with biochemical improvement and was well tolerated in infants under 1 year of age. Although no significant difference was observed between the 500 and 1000 µg regimens in this retrospective cohort, prospective noninferiority studies are needed to determine whether the lower dose is comparable with the higher dose.
- 3 September 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (7) , e323-e328
Oral Cyanocobalamin Treatment in Infants Under 1 Year With Nutritional Vitamin B12 Deficiency: A Retrospective Comparison of 500 and 1000 µg Dose Regimens
Background: Vitamin B12 deficiency is a significant health problem in infancy, particularly in developing countries. Oral treatment has emerged as an alternative to intramuscular therapy, but optimal dosing in infants remains unclear. Methods: This retrospective study included 93 infants aged 1 to 12 months diagnosed with nutritional vitamin B12 deficiency. Patients received either 500 or 1000 µg oral cyanocobalamin. Laboratory parameters were evaluated at baseline, 2 months, and 4 months. Results: Both treatment groups demonstrated significant increases in serum vitamin B12 levels and decreases in homocysteine levels ( P <0.001). No significant difference was observed between the 500 and 1000 µg groups regarding hematological or biochemical response. Treatment was well tolerated with no reported adverse effects. Conclusions: Oral cyanocobalamin was associated with biochemical improvement and was well tolerated in infants under 1 year of age. Although no significant difference was observed between the 500 and 1000 µg regimens in this retrospective cohort, prospective noninferiority studies are needed to determine whether the lower dose is comparable with the higher dose.
- 20 May 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (1) , 89-95
Evaluation of Clinical and Hematological Findings of Patients with Acute and Reactivated EBV Infection
Epstein-Barr virus (EBV) is a latent DNA virus that infects B lymphocytes, can cause widespread hematological findings, and can cause various disease manifestations. In our study, it was aimed to the clinical and hematological findings of those in the pediatric age group patients with a primary EBV infection and those with EBV reactivation. The files of the patients whose EBV serology was evaluated and followed up with the diagnosis of EBV. Patient parameters such as age, sex, clinical complaints, physical examination findings, hematologic and biochemical parameters were compared between the primary infection and reactivation groups. Of the 2200 screened patients, 204 were included in the study as EBV primary infection and 117 as EBV reactivation. Concurrent hematological findings were present in 91.1% of patients with EBV primary infection and in 90.6% of patients with reactivation. The rate of lymphocytosis in blood tests and peripheral smears in the primary infection group was significantly higher than in the reactivation group (p < 0.05). The incidence of leukopenia, lymphopenia and pancytopenia was significantly higher in the reactivation group (p < 0.05). It was observed that malignancy developed in 5.1% of the patients with EBV reactivation. This study was conducted by including a large pediatric patient population. Patients presenting with cytopenia should be evaluated for EBV reactivation, since the rate of cytopenia is high in patients in the reactivation phase. Patients with a history of EBV infection should be closely followed-up for the early diagnosis and treatment of possible late complications of EBV, especially lymphoproliferative cancers.
- 20 May 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (1) , 89-95
Evaluation of Clinical and Hematological Findings of Patients with Acute and Reactivated EBV Infection
Epstein-Barr virus (EBV) is a latent DNA virus that infects B lymphocytes, can cause widespread hematological findings, and can cause various disease manifestations. In our study, it was aimed to the clinical and hematological findings of those in the pediatric age group patients with a primary EBV infection and those with EBV reactivation. The files of the patients whose EBV serology was evaluated and followed up with the diagnosis of EBV. Patient parameters such as age, sex, clinical complaints, physical examination findings, hematologic and biochemical parameters were compared between the primary infection and reactivation groups. Of the 2200 screened patients, 204 were included in the study as EBV primary infection and 117 as EBV reactivation. Concurrent hematological findings were present in 91.1% of patients with EBV primary infection and in 90.6% of patients with reactivation. The rate of lymphocytosis in blood tests and peripheral smears in the primary infection group was significantly higher than in the reactivation group (p < 0.05). The incidence of leukopenia, lymphopenia and pancytopenia was significantly higher in the reactivation group (p < 0.05). It was observed that malignancy developed in 5.1% of the patients with EBV reactivation. This study was conducted by including a large pediatric patient population. Patients presenting with cytopenia should be evaluated for EBV reactivation, since the rate of cytopenia is high in patients in the reactivation phase. Patients with a history of EBV infection should be closely followed-up for the early diagnosis and treatment of possible late complications of EBV, especially lymphoproliferative cancers.
- 11 October 2022
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 39 (2) , 340-343
Evaluation of Asymptomatic Covid Infection in Children with Pediatric Hemato-Oncologic Disease
- 11 October 2022
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 39 (2) , 340-343
Evaluation of Asymptomatic Covid Infection in Children with Pediatric Hemato-Oncologic Disease
Non-Hodgkin lenfomanın farkı mukozal görünümleri: Olgu serisi
Non-Hodgkin lymphoma has an incidence 8% of all childhood malignancies in the world. Non-Hodgkin lymphoma typically invades the liver, lungs, spleen and mediastinum. The most common symptoms include pain and coughing due to enlarged lymph nodes, shortness of breath due to thoracic masses, and bowel obstruction and acid in abdominal involvement. In this study, we have discussed cases of lymphoma with different mucosal presentations. The age of the patients varied from 3.5-16 years, and included three females and two males. The cases include patients with lymphoblastic lymphoma referring with a preliminary diagnosis of eosinophilic granuloma; with lymphoblastic lymphoma, with a preliminary diagnosis of odontogenic cyst; with Burkitt lymphoma, with lower gastrointestinal system bleeding-acute gastroenteritis; with Burkitt lymphoma, with a preliminary diagnosis of ovarian tumor and with diffuse large B-cell lymphoma, with a diagnosis of anemia. Clinical, laboratory and radiological diagnostic methods can guide diagnosis of lymphoma, histopathologic examination is important for the final diagnosis. In conclusion, it is important to make a systemic evaluation rather than focusing only on the referral complaints and radiological imaging in patient assessment.
Non-Hodgkin lenfomanın farkı mukozal görünümleri: Olgu serisi
Non-Hodgkin lymphoma has an incidence 8% of all childhood malignancies in the world. Non-Hodgkin lymphoma typically invades the liver, lungs, spleen and mediastinum. The most common symptoms include pain and coughing due to enlarged lymph nodes, shortness of breath due to thoracic masses, and bowel obstruction and acid in abdominal involvement. In this study, we have discussed cases of lymphoma with different mucosal presentations. The age of the patients varied from 3.5-16 years, and included three females and two males. The cases include patients with lymphoblastic lymphoma referring with a preliminary diagnosis of eosinophilic granuloma; with lymphoblastic lymphoma, with a preliminary diagnosis of odontogenic cyst; with Burkitt lymphoma, with lower gastrointestinal system bleeding-acute gastroenteritis; with Burkitt lymphoma, with a preliminary diagnosis of ovarian tumor and with diffuse large B-cell lymphoma, with a diagnosis of anemia. Clinical, laboratory and radiological diagnostic methods can guide diagnosis of lymphoma, histopathologic examination is important for the final diagnosis. In conclusion, it is important to make a systemic evaluation rather than focusing only on the referral complaints and radiological imaging in patient assessment.
- Open Access
- 17 March 2020
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 37 (3) , 139-144
OUTCOMES OF ELTROMBOPAG TREATMENT AND DEVELOPMENT OF IRON DEFICIENCY IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA IN TURKEY
Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children. Materials and Methods: The present retrospective study evaluated the efficacy, safety, and side effects of EPAG treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia, particularly focusing on iron-deficiency anemia. Results: The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5 +/- 4.5 years (minimum-maximum: 1.2-18 years) at the beginning of EPAG treatment. The overall response rate was 74.3% (n=78). The mean time for platelet count of >= 50x109/L was 11.6 +/- 8 weeks (range: 1-34 weeks). The treatment was stopped for 27 patients (25.7%) at an average of 6.8 +/- 9 months (range: 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for an average of 4 months after cessation of EPAG in 3 patients. Conclusion: Results of the current study imply that EPAG is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects during treatment, and especially for iron deficiency.
- 17 March 2020
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 37 (3) , 139-144
Open AccessOUTCOMES OF ELTROMBOPAG TREATMENT AND DEVELOPMENT OF IRON DEFICIENCY IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA IN TURKEY
Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children. Materials and Methods: The present retrospective study evaluated the efficacy, safety, and side effects of EPAG treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia, particularly focusing on iron-deficiency anemia. Results: The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5 +/- 4.5 years (minimum-maximum: 1.2-18 years) at the beginning of EPAG treatment. The overall response rate was 74.3% (n=78). The mean time for platelet count of >= 50x109/L was 11.6 +/- 8 weeks (range: 1-34 weeks). The treatment was stopped for 27 patients (25.7%) at an average of 6.8 +/- 9 months (range: 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for an average of 4 months after cessation of EPAG in 3 patients. Conclusion: Results of the current study imply that EPAG is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects during treatment, and especially for iron deficiency.
- Open Access
- 31 December 2019
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 13 (4) , 141-146
Pediatric Neutropenic Patients Care in Turkey
- 31 December 2019
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 13 (4) , 141-146
Open AccessPediatric Neutropenic Patients Care in Turkey
- 31 December 2019
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 13 (4) , 177-182
Türkiye’ de Pediatrik Nötropenik Hasta İzlemi
- 31 December 2019
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 13 (4) , 177-182
Türkiye’ de Pediatrik Nötropenik Hasta İzlemi
- 30 May 2018
- Published by Lycia Press London UK in Medical Science and Discovery
- Vol. 5 (5) , 202-206
T-cell Non-Hodgkin lymphoma associated with myelodysplasia: A case report in a child
Myelodysplastic syndrome (MDS) is a clonal bone marrow disease characterized by ineffective erythropoiesis. MDS patients have cytopenia. The risk of acute leukemia, and particularly of acute myeloblastic leukemia (AML), is the most important characteristic of the disease. Myelodysplasia associated with NHL has been rarely described in the literature. This is suggested to be due to the defect in the immune system, an up-regulation of some cytokines, and a common molecular origin. In this case report article, we reported a 7-year-old pediatric NHL case with a normal karyotype and myelodysplasia in the bone marrow and discussed the pathogenesis of the association of NHL and myelodysplasia.
- 30 May 2018
- Published by Lycia Press London UK in Medical Science and Discovery
- Vol. 5 (5) , 202-206
T-cell Non-Hodgkin lymphoma associated with myelodysplasia: A case report in a child
Myelodysplastic syndrome (MDS) is a clonal bone marrow disease characterized by ineffective erythropoiesis. MDS patients have cytopenia. The risk of acute leukemia, and particularly of acute myeloblastic leukemia (AML), is the most important characteristic of the disease. Myelodysplasia associated with NHL has been rarely described in the literature. This is suggested to be due to the defect in the immune system, an up-regulation of some cytokines, and a common molecular origin. In this case report article, we reported a 7-year-old pediatric NHL case with a normal karyotype and myelodysplasia in the bone marrow and discussed the pathogenesis of the association of NHL and myelodysplasia.
- Open Access
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 1 (1) , 151-156
Augmented mitochondrial cytochrome c oxidase activity in children with iron deficiency: a tandem between iron and copper?
Introduction: Dyshomeostasis of essential trace elements including iron and copper plays a key role in the pathogenesis of a myriad of serious conditions including iron deficiency (ID) anemia, in which impaired cellular energy metabolism is prominent. Although experimental studies documented...
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 1 (1) , 151-156
Open AccessAugmented mitochondrial cytochrome c oxidase activity in children with iron deficiency: a tandem between iron and copper?
Introduction: Dyshomeostasis of essential trace elements including iron and copper plays a key role in the pathogenesis of a myriad of serious conditions including iron deficiency (ID) anemia, in which impaired cellular energy metabolism is prominent. Although experimental studies documented...
- 1 May 2017
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 39 (4) , 323-325
Remission Following Paclitaxel and Cisplatin Treatment in a 15-Year-Old Patient With Unresectable Esophageal Squamous Cell Cancer
- 1 May 2017
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 39 (4) , 323-325
Remission Following Paclitaxel and Cisplatin Treatment in a 15-Year-Old Patient With Unresectable Esophageal Squamous Cell Cancer